Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish
a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and …

Patient-derived xenografts (PDXs) are tools of the trade for many researchers from all
disciplines and medical specialties. Most endocrinologists, and especially those working in …

New treatments are required for advanced prostate cancer; however, there are fewer
preclinical models of prostate cancer than other common tumor types to test candidate …

Patient-derived xenografts (PDXs) are generated by engrafting human tumours into mice.
Serially transplantable PDXs are used to study tumour biology and test therapeutics, linking …

Potent therapeutic inhibition of the androgen receptor (AR) in prostate adenocarcinoma can
lead to the emergence of neuroendocrine prostate cancer (NEPC), a phenomenon …

As the treatment landscape for prostate cancer gradually evolves, the frequency of treatment-
induced neuroendocrine prostate cancer (NEPC) and double-negative prostate cancer …

Background Prostate cancer is dependent on androgen receptor (AR) signaling, and
androgen deprivation therapy (ADT) has proven effective in targeting prostate cancer …

Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive malignancy with
poor outcomes. To investigate novel therapeutic strategies, we characterized three new …

Scientists engaged in prostate cancer research have been conducting experiments using
two‐dimensional cultures of prostate cancer cell lines for decades. However, these …

The engraftment of human tumor tissues into immunodeficient host mice to generate patient-
derived xenograft (PDX) models has become increasingly utilized for many types of cancers …